K.R.R. Drugs & Intermediates Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 26-07-2024
- Paid Up Capital ₹ 2.50 M
as on 26-07-2024
- Company Age 22 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 15.43 Cr
as on 26-07-2024
- Revenue %
(FY 2023)
- Profit -7.32%
(FY 2023)
- Ebitda -15.72%
(FY 2023)
- Net Worth -23.43%
(FY 2023)
- Total Assets -5.99%
(FY 2023)
About K.R.R. Drugs & Intermediates
The Corporate was formerly known as Medeva Laboratories Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 2.50 M.
The company has closed loans amounting to ₹15.43 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sundeep Kattamuri and Subbarao Kattamuri serve as directors at the Company.
- CIN/LLPIN
U24239AP2002PTC038417
- Company No.
038417
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jan 2002
- Date of AGM
31 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Ameerpet, Hyderabad., Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does K.R.R. Drugs & Intermediates Private Limited offer?
K.R.R. Drugs & Intermediates Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Anti Infective API.
Who are the key members and board of directors at K.R.R. Drugs & Intermediates?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sundeep Kattamuri  | Director | 08-Jul-2015 | Current |
| Subbarao Kattamuri | Director | 08-Jul-2015 | Current |
Financial Performance and Corporate Structure Insights of K.R.R. Drugs & Intermediates.
K.R.R. Drugs & Intermediates Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 7.32% decrease in profit. The company's net worth observed a substantial decline by a decrease of 23.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of K.R.R. Drugs & Intermediates?
In 2023, K.R.R. Drugs & Intermediates had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Priche Generics Private LimitedActive 8 years 2 monthsSundeep Kattamuri and Subbarao Kattamuri are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Syndicate Bank Creation Date: 04 Oct 2014 | ₹7.40 Cr | Satisfied |
Syndicate Bank Creation Date: 01 Aug 2005 | ₹2.75 Cr | Satisfied |
Syndicate Bank Creation Date: 01 Aug 2005 | ₹1.14 Cr | Satisfied |
How Many Employees Work at K.R.R. Drugs & Intermediates?
K.R.R. Drugs & Intermediates has a workforce of 6 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of K.R.R. Drugs & Intermediates, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped K.R.R. Drugs & Intermediates's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
